EARNINGS PER SHARE INFORMATION

12 Months Ended

Dec. 31, 2022

NOTE 18. EARNINGS PER SHARE INFORMATION


	2022				2021				2020
(Earnings for per-share calculation, shares in millions, per-share amounts in dollars)	Diluted		Basic		Diluted		Basic		Diluted		Basic


Earnings (loss) from continuing operations	$	869	$	869	$	(3,326)	$	(3,326)	$	6,601	$	6,601
Preferred stock dividends	(289)		(289)		(237)		(237)		(474)		(474)
Accretion of redeemable noncontrolling interests, net of tax	—		—		(9)		(9)		(151)		(151)
Accretion of preferred share repurchase	4		4		—		—		—		—
Earnings (loss) from continuing operations attributable to common shareholders	584		584		(3,571)		(3,571)		5,975		5,975
Earnings (loss) from discontinued operations	(644)		(644)		(3,195)		(3,195)		(909)		(909)
Net earnings (loss) attributable to GE common shareholders	(60)		(60)		(6,766)		(6,766)		5,066		5,066

Shares of GE common stock outstanding	1,096		1,096		1,098		1,098		1,094		1,094
Employee compensation-related shares (including stock options)	6		—		—		—		1		—
Total average equivalent shares	1,101		1,096		1,098		1,098		1,095		1,094

Earnings (loss) from continuing operations	$	0.53	$	0.53	$	(3.25)	$	(3.25)	$	5.46	$	5.46
Earnings (loss) from discontinued operations	(0.58)		(0.59)		(2.91)		(2.91)		(0.83)		(0.83)
Net earnings (loss) per share	(0.05)		(0.06)		(6.16)		(6.16)		4.63		4.63

Potentially dilutive securities(a)	44				41				56

(a) Outstanding stock awards not included in the computation of diluted earnings (loss) per share because their effect was antidilutive.

Our unvested restricted stock unit awards that contain non-forfeitable rights to dividends or dividend equivalents are considered participating securities and, therefore, are included in the computation of earnings per share pursuant to the two-class method. For the year ended December 31, 2022, application of this treatment had an insignificant effect. For the year ended December 31, 2021, as a result of the loss from continuing operations, losses were not allocated to the participating securities. For the year ended December 31, 2020, application of this treatment had an insignificant effect.